Product Description
Cycloserine is a broad spectrum antibiotic used as a second line agent for treatment of drug resistant tuberculosis, always in combination with other antituberculosis agents. Cycloserine is appears to have little or no hepatotoxic potential, but it is usually used in combination with agents that are known to be hepatotoxic, and its role in the reported cases of liver injury with combination therapy cannot always be excluded. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cycloserine)
Mechanisms of Action: L-Alanine Racemase Inhibitor,D-Alanine Ligase Inhibitor,Cell Wall Synthesis Inhibitor,NMDA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Canada | Chile | Colombia | Dominican Republic | Greece | Hong Kong | India | Ireland | Korea | Lithuania | Malaysia | Malta | Mexico | New Zealand | Pakistan | Peru | Philippines | Romania | Russia | Slovenia | South Africa | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT03401164 | P2 |
Not yet recruiting |
Depressive Disorder, Major |
2019-12-01 |